BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism 2016;65:1007-16. [DOI: 10.1016/j.metabol.2015.12.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Nobakht M. Gh BF, Hasani Nourian Y, Arabfard M. Identification of Shared Gene Signatures in Different Stages of Nonalcoholic Fatty Liver Disease Using Integrated Microarray Datasets. Hepat Mon 2022;22. [DOI: 10.5812/hepatmon-122362] [Reference Citation Analysis]
2 Bao S, Wang X, Ma Q, Wei C, Nan J, Ao W. Mongolian medicine in treating type 2 diabetes mellitus combined with nonalcoholic fatty liver disease via FXR/LXR-mediated P2X7R/NLRP3/NF-κB pathway activation. Chinese Herbal Medicines 2022. [DOI: 10.1016/j.chmed.2022.06.003] [Reference Citation Analysis]
3 Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Curr Obes Rep 2022. [PMID: 35501557 DOI: 10.1007/s13679-022-00474-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Araújo MC, Soczek SHS, Pontes JP, Marques LAC, Santos GS, Simão G, Bueno LR, Maria-Ferreira D, Muscará MN, Fernandes ES. An Overview of the TRP-Oxidative Stress Axis in Metabolic Syndrome: Insights for Novel Therapeutic Approaches. Cells 2022;11:1292. [PMID: 35455971 DOI: 10.3390/cells11081292] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pafili K, Paschou SA, Armeni E, Polyzos SA, Goulis DG, Lambrinoudaki I. Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. J Endocrinol Invest 2022. [PMID: 35303270 DOI: 10.1007/s40618-022-01766-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sangouni AA, Orang Z, Mozaffari-Khosravi H. Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial. BMC Nutr 2021;7:86. [PMID: 34911587 DOI: 10.1186/s40795-021-00490-8] [Reference Citation Analysis]
7 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
8 Kim SH, Jung YJ, Ko MS, Lee SW, Lee JS, Oh YM. Prevalence of asymptomatic bronchiectasis and associations among the health screening population in South Korea. ERJ Open Res 2021;7:00188-2021. [PMID: 34350287 DOI: 10.1183/23120541.00188-2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, Filimidou I, Karagianni M, Anastasilakis D, Evripidou K, Ftergioti A, Togkaridou M, Tsaftaridis N, Apostolopoulos A, Polyzos SA. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34289181 DOI: 10.1111/jgh.15631] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
10 Polyzos SA, Kountouras J, Anastasilakis AD. Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis. Metabolism 2021;121:154818. [PMID: 34153303 DOI: 10.1016/j.metabol.2021.154818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Makri ES, Goulas A, Polyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 2021;907:174272. [PMID: 34147478 DOI: 10.1016/j.ejphar.2021.174272] [Reference Citation Analysis]
12 Wang K, Tan W, Liu X, Deng L, Huang L, Wang X, Gao X. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. Biomed Pharmacother 2021;137:111326. [PMID: 33556870 DOI: 10.1016/j.biopha.2021.111326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 AlFaris NA, Alshammari GM, AlTamimi JZ, AlMousa LA, AlKehayez NM, Aljabryn DH, Alagal RI, Yahya MA. The protective effect of shrimp cooked in different methods on high-cholesterol- induced fatty liver in rats. Saudi J Biol Sci 2021;28:170-82. [PMID: 33424294 DOI: 10.1016/j.sjbs.2020.09.036] [Reference Citation Analysis]
14 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
15 Polyzos SA, Perakakis N, Boutari C, Kountouras J, Ghaly W, Anastasilakis AD, Karagiannis A, Mantzoros CS. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. J Clin Endocrinol Metab 2020;105:dgz172. [PMID: 31690932 DOI: 10.1210/clinem/dgz172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
16 Makri E, Kita M, Goulas A, Papaioannidou P, Efstathiadou ZA, Adamidou F, Polyzos SA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr 2020;14:1913-9. [PMID: 33011499 DOI: 10.1016/j.dsx.2020.09.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
17 Shabalala SC, Dludla PV, Mabasa L, Kappo AP, Basson AK, Pheiffer C, Johnson R. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother 2020;131:110785. [PMID: 33152943 DOI: 10.1016/j.biopha.2020.110785] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
18 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
19 Doulberis M, Papadimitriou K, Papaefthymiou A, Kountouras J, Polyzos SA. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine 2020;1:170-83. [DOI: 10.37349/emed.2020.00012] [Reference Citation Analysis]
20 Venetsanaki V, Polyzos SA. Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives. Curr Vasc Pharmacol. 2019;17:546-555. [PMID: 29992886 DOI: 10.2174/1570161116666180711121949] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
21 Sangouni AA, Mohammad Hosseini Azar MR, Alizadeh M. Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial. Br J Nutr 2020;124:450-6. [PMID: 32312333 DOI: 10.1017/S0007114520001403] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
22 Polyzos SA, Kountouras J, Mantzoros CS. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns. Metabolism 2020;104:154144. [DOI: 10.1016/j.metabol.2020.154144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
23 Polyzos SA, Hawa G, Jungwirth T, Karabouta Z, Kountouras J. Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment. Hormones 2019;18:519-21. [DOI: 10.1007/s42000-019-00135-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
24 Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C, Lambrinoudaki I, Georgopoulos NA, Vryonidou A. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 2020;67:1-8. [PMID: 31538291 DOI: 10.1007/s12020-019-02085-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
25 Venetsanaki V, Karabouta Z, Polyzos SA. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. Eur J Pharmacol. 2019;863:172661. [PMID: 31536725 DOI: 10.1016/j.ejphar.2019.172661] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
26 Polyzos SA, Kountouras J, Goulas A, Duntas L. Selenium and selenoprotein P in nonalcoholic fatty liver disease. Hormones (Athens) 2020;19:61-72. [PMID: 31493247 DOI: 10.1007/s42000-019-00127-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
27 Polyzos SA, Kountouras J, Mantzoros CS. Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction? Metabolism 2019;96:iii-v. [DOI: 10.1016/j.metabol.2019.05.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
28 Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism 2019;96:66-82. [PMID: 31071311 DOI: 10.1016/j.metabol.2019.05.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 16.3] [Reference Citation Analysis]
29 Polyzos SA, Kountouras J. Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy. Helicobacter 2019;24:e12588. [DOI: 10.1111/hel.12588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
30 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 306] [Cited by in F6Publishing: 289] [Article Influence: 102.0] [Reference Citation Analysis]
31 Buznytska OV; Kharkіv Medical Academy of Postgraduate Education,V. N. Karazin Kharkіv National University, Ukraine. Diagnostic significance of biochemical indicators of liver fibrogenesis in adolescents with obesity. Ukr Biochem J 2019;91:74-9. [DOI: 10.15407/ubj91.01.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Polyzos SA, Kountouras J, Anastasilakis AD, Makras P, Hawa G, Sonnleitner L, Missbichler A, Doulberis M, Katsinelos P, Terpos E. Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. Hormones 2018;17:573-9. [DOI: 10.1007/s42000-018-0083-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Katsiki N, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation? Metabolism 2018;87:A10-3. [DOI: 10.1016/j.metabol.2018.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
34 Kurniawan DW, Jajoriya AK, Dhawan G, Mishra D, Argemi J, Bataller R, Storm G, Mishra DP, Prakash J, Bansal R. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. J Control Release. 2018;288:227-238. [PMID: 30219279 DOI: 10.1016/j.jconrel.2018.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
35 Moon SW, Kim SY, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Ro JS, Lee YH, Lee SH. Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010. Int J Chron Obstruct Pulmon Dis 2018;13:2603-11. [PMID: 30214178 DOI: 10.2147/COPD.S166902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
36 Chartampilas E. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones (Athens) 2018;17:69-81. [PMID: 29858854 DOI: 10.1007/s42000-018-0012-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
37 Li D, Liu J, Hua X, Fu H, Huang F, Fei Y, Lu W, Shen F, Wang P. Nicotinic acetylcholine receptor α7 subunit improves energy homeostasis and inhibits inflammation in nonalcoholic fatty liver disease. Metabolism 2018;79:52-63. [DOI: 10.1016/j.metabol.2017.11.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
38 Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43. [PMID: 29589386 DOI: 10.3803/enm.2018.33.1.33] [Cited by in Crossref: 61] [Cited by in F6Publishing: 80] [Article Influence: 15.3] [Reference Citation Analysis]
39 Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism 2018;86:33-43. [PMID: 29024702 DOI: 10.1016/j.metabol.2017.09.016] [Cited by in Crossref: 107] [Cited by in F6Publishing: 81] [Article Influence: 21.4] [Reference Citation Analysis]
40 Polyzos SA, Duntas L, Bollerslev J. The intriguing connections of leptin to hyperparathyroidism. Endocrine 2017;57:376-87. [DOI: 10.1007/s12020-017-1374-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
41 Viglino D, Jullian-desayes I, Minoves M, Aron-wisnewsky J, Leroy V, Zarski J, Tamisier R, Joyeux-faure M, Pépin J. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J 2017;49:1601923. [DOI: 10.1183/13993003.01923-2016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
42 Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2016;17:1937-46. [DOI: 10.1080/14656566.2016.1225727] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
43 Polyzos SA, Bugianesi E, Kountouras J, Mantzoros CS. Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. Metabolism 2017;66:64-8. [PMID: 27594084 DOI: 10.1016/j.metabol.2016.08.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
44 Polyzos SA, Kountouras J, Anastasilakis AD, Triantafyllou GΑ, Mantzoros CS. Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism 2016;65:1550-8. [PMID: 27621190 DOI: 10.1016/j.metabol.2016.07.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]